Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). Deming, D. A., Ahnert, J., Demeure, M. J., Federman, N., McKean, M., Lee, E., Spira, A. I., Kwiatkowski, D. J., Hussein, M. A., Gordon, E., Crockett, D. G., Ganjoo, K. N., Schulte, B., Cranmer, L. D., Schmid, A. N., Navarro, W. H., Itri, L., Iyer, G. LIPPINCOTT WILLIAMS & WILKINS. 2023: TPS818

View details for Web of Science ID 001093994600106